- Previous Close
1.8500 - Open
2.0500 - Bid 1.8400 x 100
- Ask 1.8500 x 200
- Day's Range
1.8000 - 2.0500 - 52 Week Range
1.7500 - 4.9700 - Volume
55,118 - Avg. Volume
72,521 - Market Cap (intraday)
25.653M - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5300 - Earnings Date Feb 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.88
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
www.gracetx.comRecent News: GRCE
View More
Performance Overview: GRCE
Trailing total returns as of 4/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GRCE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GRCE
View MoreValuation Measures
Market Cap
24.69M
Enterprise Value
1.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.47
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.16%
Return on Equity (ttm)
-22.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.37M
Diluted EPS (ttm)
-1.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
11.05M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-8.49M